117. Chen W, Zhao W, Zhang L et al (2017) MALAT1-miR-101-SOX9 feedback loop modulates
the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget
8:94317–94329
118. Cai T, Liu Y, Xiao J (2017) Long noncoding RNA MALAT1 knockdown reverses
chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer
Med 7:1–12. https://doi.org/10.1002/cam4.1384
119. Malakar P, Shilo A, Mogilevsky A et al (2017) Long noncoding RNA MALAT1 promotes
hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation.
Cancer Res 77:1155–1167. https://doi.org/10.1158/0008-5472.CAN-16-1508
120. Wang J, Wang H, Zhang Y et al (2014) Mutual inhibition between YAP and SRSF1 maintains
long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. Cell Signal
26:1048–1059. https://doi.org/10.1016/j.cellsig.2014.01.022
121. Li C, Miao R, Liu S et al (2017) Down-regulation of miR-146b-5p by long noncoding RNA
MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget
8:28683–28695. https://doi.org/10.18632/oncotarget.15640
122. Yuan P, Cao W, Zang Q et al (2016) The HIF-2α-MALAT1-miR-216b axis regulates multidrug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem Biophys
Res Commun 478:1067–1073. https://doi.org/10.1016/j.bbrc.2016.08.065
123. Ji Q, Zhang L, Liu X et al (2014) Long non-coding RNA MALAT1 promotes tumour growth
and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2
from SFPQ/PTBP2 complex. Br J Cancer 111:736–748. https://doi.org/10.1038/bjc.2014.383
124. Li P, Zhang X, Wang H et al (2017) MALAT1 is associated with poor response to oxaliplatinbased chemotherapy in colorectal cancer patients and promotes chemoresistance through
EZH2. Mol Cancer Ther 16:739–751. https://doi.org/10.1158/1535-7163.MCT-16-0591
125. Dong Y, Liang G, Yuan B et al (2014) MALAT1 promotes the proliferation and metastasis
of osteosarcoma cells by activating the PI3K/Akt pathway. Tumor Biol 36:1477–1486. https://
doi.org/10.1007/s13277-014-2631-4
126. Zhang Z-C, Tang C, Dong Y et al (2017) Targeting the long noncoding RNA MALAT1
blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth. Int J Biol
Sci 13:1398–1408. https://doi.org/10.7150/ijbs.22249
127. Luan T, Zhang X, Wang S et al (2017) Long non-coding RNA MIAT promotes breast cancer
progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p.
Oncotarget 8:1–12. https://doi.org/10.18632/oncotarget.19190
128. Zhang H-Y, Zheng F-S, Yang W, Lu J-B (2017) The long non-coding RNA MIAT regulates
zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoting cell
invasion in non-small-cell lung cancer. Gene 633:61–65. https://doi.org/10.1016/j.gene.2017.
08.009
129. Fu Y, Li C, Luo Y et al (2018) Silencing of long non-coding RNA MIAT sensitizes lung
cancer cells to gefitinib by epigenetically regulating miR-34a. Front Pharmacol 9:1–12. https://
doi.org/10.3389/fphar.2018.00082
130. Cai H, Xue Y, Wang P et al (2015) The long noncoding RNA TUG1 regulates blood-tumor
barrier permeability by targeting miR-144. Oncotarget 6:19759–19779. https://doi.org/10.
18632/oncotarget.4331
131. Wang PQ, Wu YX, Zhong XD et al (2017) Prognostic significance of overexpressed long
non-coding RNA TUG1 in patients with clear cell renal cell carcinoma. Eur Rev Med
Pharmacol Sci 21:82–86
132. Wang Y, Yang T, Zhang Z et al (2017) Long non-coding RNA TUG1 promotes migration and
invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells. Cancer Sci 108:859–867.
https://doi.org/10.1111/cas.13201
133. Zhang Q, Geng P-L, Yin P et al (2013) Down-regulation of long non-coding RNA TUG1
inhibits osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J Cancer Prev
14:2311–2315. https://doi.org/10.7314/APJCP.2013.14.4.2311
Altered Long Non-coding RNA Expression in Cancer: Potential Biomarkers. . .
427
the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget
8:94317–94329
118. Cai T, Liu Y, Xiao J (2017) Long noncoding RNA MALAT1 knockdown reverses
chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer
Med 7:1–12. https://doi.org/10.1002/cam4.1384
119. Malakar P, Shilo A, Mogilevsky A et al (2017) Long noncoding RNA MALAT1 promotes
hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation.
Cancer Res 77:1155–1167. https://doi.org/10.1158/0008-5472.CAN-16-1508
120. Wang J, Wang H, Zhang Y et al (2014) Mutual inhibition between YAP and SRSF1 maintains
long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. Cell Signal
26:1048–1059. https://doi.org/10.1016/j.cellsig.2014.01.022
121. Li C, Miao R, Liu S et al (2017) Down-regulation of miR-146b-5p by long noncoding RNA
MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget
8:28683–28695. https://doi.org/10.18632/oncotarget.15640
122. Yuan P, Cao W, Zang Q et al (2016) The HIF-2α-MALAT1-miR-216b axis regulates multidrug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem Biophys
Res Commun 478:1067–1073. https://doi.org/10.1016/j.bbrc.2016.08.065
123. Ji Q, Zhang L, Liu X et al (2014) Long non-coding RNA MALAT1 promotes tumour growth
and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2
from SFPQ/PTBP2 complex. Br J Cancer 111:736–748. https://doi.org/10.1038/bjc.2014.383
124. Li P, Zhang X, Wang H et al (2017) MALAT1 is associated with poor response to oxaliplatinbased chemotherapy in colorectal cancer patients and promotes chemoresistance through
EZH2. Mol Cancer Ther 16:739–751. https://doi.org/10.1158/1535-7163.MCT-16-0591
125. Dong Y, Liang G, Yuan B et al (2014) MALAT1 promotes the proliferation and metastasis
of osteosarcoma cells by activating the PI3K/Akt pathway. Tumor Biol 36:1477–1486. https://
doi.org/10.1007/s13277-014-2631-4
126. Zhang Z-C, Tang C, Dong Y et al (2017) Targeting the long noncoding RNA MALAT1
blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth. Int J Biol
Sci 13:1398–1408. https://doi.org/10.7150/ijbs.22249
127. Luan T, Zhang X, Wang S et al (2017) Long non-coding RNA MIAT promotes breast cancer
progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p.
Oncotarget 8:1–12. https://doi.org/10.18632/oncotarget.19190
128. Zhang H-Y, Zheng F-S, Yang W, Lu J-B (2017) The long non-coding RNA MIAT regulates
zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoting cell
invasion in non-small-cell lung cancer. Gene 633:61–65. https://doi.org/10.1016/j.gene.2017.
08.009
129. Fu Y, Li C, Luo Y et al (2018) Silencing of long non-coding RNA MIAT sensitizes lung
cancer cells to gefitinib by epigenetically regulating miR-34a. Front Pharmacol 9:1–12. https://
doi.org/10.3389/fphar.2018.00082
130. Cai H, Xue Y, Wang P et al (2015) The long noncoding RNA TUG1 regulates blood-tumor
barrier permeability by targeting miR-144. Oncotarget 6:19759–19779. https://doi.org/10.
18632/oncotarget.4331
131. Wang PQ, Wu YX, Zhong XD et al (2017) Prognostic significance of overexpressed long
non-coding RNA TUG1 in patients with clear cell renal cell carcinoma. Eur Rev Med
Pharmacol Sci 21:82–86
132. Wang Y, Yang T, Zhang Z et al (2017) Long non-coding RNA TUG1 promotes migration and
invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells. Cancer Sci 108:859–867.
https://doi.org/10.1111/cas.13201
133. Zhang Q, Geng P-L, Yin P et al (2013) Down-regulation of long non-coding RNA TUG1
inhibits osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J Cancer Prev
14:2311–2315. https://doi.org/10.7314/APJCP.2013.14.4.2311
Altered Long Non-coding RNA Expression in Cancer: Potential Biomarkers. . .
427